CAR T-Cell Therapy

The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

As its CAR T cell and high-affinity TCR products continue to advance in clinical trials, Juno Therapeutics, Inc, filed a registration statement for an initial public offering (IPO) of its common stock on November 17.

Recent news stories profiling a cancer patient whose last hope rests on treatment by injections of the virus that causes AIDS may have created some misconceptions regarding a new cancer immunotherapy.

The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, but at the same time, America’s medical community should work harder to avoid the screen’s potential pitfalls.

A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

The human epidermal growth factor receptors (known as the HER family) play a pivotal role in transmitting signals that regulate cell growth and survival.

Renier J. Brentjens, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of CAR-modified T cells for the treatment of solid tumors.

Cameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.